CXCL5 and diabetes mellitus: Inhibition of CXCL5 by neutralizing antibody improved EPC function from type 2 DM patients with enhanced VEGF and SDF-1 expression, and the results were the same in the HG-stimulated HAECs and EPCs from non-DM subjects.